Phase I/II study of carboplatin with weekly ifostamide and docetaxel in recurrent or metastatic head and neck squamous cell cancers (HN-SCC).

被引：0
|
作者：
Chauhan, B [1 ]
Wanebo, H [1 ]
Rathore, R [1 ]
Chougule, P [1 ]
Kennedy, T [1 ]
Ready, N [1 ]
机构：
[1] Brown Univ, Oncol Grp, Providence, RI 02912 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5601
引用
收藏
页码：513S / 513S
页数：1
相关论文
共 50 条
  • [31] A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).
    Sabichi, A. L.
    Kies, M. S.
    Glisson, B. S.
    Lu, C.
    Ginsberg, L. E.
    Bartos, C. I.
    Feng, L.
    Tran, H. T.
    Lippman, S. M.
    Blumenschein, G. R., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study
    Stier, S
    Koll, C
    Neuhaus, T
    Fronhoffs, S
    Forkert, R
    Tuohimaa, A
    Vetter, H
    Ko, Y
    ANTI-CANCER DRUGS, 2005, 16 (10) : 1115 - 1121
  • [33] Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (NNSCC).
    Kim, ES
    Kies, M
    Sabichi, A
    Ginsberg, L
    Burke, B
    Holsinger, C
    Feng, L
    Truong, MT
    Glisson, B
    Hong, WK
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 511S - 511S
  • [34] Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC).
    Kim, E. S.
    Kies, M. S.
    Glisson, B. S.
    Ginsberg, L. E.
    Holsinger, F. C.
    Burke, B. J.
    Truong, M.
    Tsao, A. S.
    Hong, W. K.
    Lippman, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 285S - 285S
  • [35] Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas
    William, William N., Jr.
    Tsao, Anne S.
    Feng, Lei
    Ginsberg, Lawrence E.
    Lee, J. Jack
    Kies, Merrill S.
    Glisson, Bonnie S.
    Kim, Edward S.
    ONCOLOGIST, 2018, 23 (05): : 526 - +
  • [36] Vinorelbine and carboplatin in recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Kornek, V
    Scheithauer, W
    Glaser, C
    Toth, J
    Duman, M
    Formanek, M
    Hejna, M
    Kornfehl, J
    ONCOLOGY, 1999, 56 (01) : 24 - 27
  • [37] A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck
    Wang, Tso-Fu
    Chu, Sung-Chao
    Kao, Ruey-Ho
    Yao, Chao-Yuan
    Li, Chi-Cheng
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (07) : 459 - 463
  • [38] A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Lee, Ji Hyun
    Heo, Seong Gu
    Ahn, Beung-Chul
    Hong, Min Hee
    Cho, Byoung Chul
    Lim, Sun Min
    Kim, Hye Ryun
    CANCER MEDICINE, 2021, 10 (20): : 7012 - 7020
  • [39] A phase II trial of docetaxel plus cisplatin in recurrent and/or metastatic non-squamous cell carcinoma of head and neck
    Imamura, Y.
    Kiyota, N.
    Tanaka, K.
    Hayashi, H.
    Ota, I.
    Nario, K.
    Hirano, S.
    Arai, A.
    Iwae, S.
    Onoe, T.
    Minami, S.
    Shimada, T.
    Yane, K.
    Yamazaki, T.
    Nagatani, Y.
    Toyoda, M.
    Otsuki, N.
    Nibu, K-I.
    Minami, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [40] Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
    Cohen, Ezra E. W.
    Davis, Darren W.
    Karrison, Theodore G.
    Seiwert, Tanguy Y.
    Wong, Stuart J.
    Nattam, Sreenivasa
    Kozloff, Mark F.
    Clark, Joseph I.
    Yan, Duen-Hwa
    Liu, Wen
    Pierce, Carolyn
    Dancey, Janet E.
    Stenson, Kerstin
    Blair, Elizabeth
    Dekker, Allison
    Vokes, Everett E.
    LANCET ONCOLOGY, 2009, 10 (03): : 247 - 257
12345